The controversial healthcare conglomerate is accused of systematically diagnosing patients with as many conditions as ...
Ollin Biosciences’ VEGF/Ang2 bispecific antibody has shown superiority over Roche’s Vabysmo (faricimab) in a head-to-head ...
Medtronic Diabetes has expanded U.S. pharmacy formulary access for its MiniMed 780F insulin pump through agreements with ...
Ollin Biosciences has announced positive topline results from its randomized, head-to-head Phase 1b JADE clinical study ...
Money Talks News on MSN
Doctors are missing type 1.5 diabetes in thousands of patients diagnosed with type 2
Type 1.5 diabetes affects up to 12% of adults but gets misdiagnosed as type 2. Find out if your symptoms match this hidden ...
Federal health officials have laid out a new plan to expand access to GLP-1 drugs for weight loss and diabetes, signaling a ...
Multiple milestones anticipated from late-stage portfolio including topline results from DIAMOND Phase 3 trials with OCS-01 ...
Ollin Biosciences Inc. is gearing up for global phase III trials this year after disclosing favorable top-line results from its randomized, head-to-head phase Ib Jade study comparing OLN-324, a ...
Panelists discuss how clinicians manage suboptimal responders by focusing on stability rather than complete dryness, using ...
As California ends Medicaid coverage for GLP-1 weight loss drugs like Wegovy and Zepbound, experts say the state's advice to ...
KFF Health News on MSN
Older Americans Quit Weight-Loss Drugs in Droves
The post Older Americans Quit Weight-Loss Drugs in Droves appeared first on Katie Couric Media.
Phase 3 programs underway for DURAVYU in wet AMD and DME, the largest multi-billion-dollar retinal disease markets –– Pivotal Phase 3 trials in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback